---
title: Map rescue medication dosing patterns
nct_id: NCT07145190
status: RECRUITING
sponsor: Bial - Portela C S.A.
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07145190"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07145190"
last_fetched: "2026-05-10T14:06:46.516Z"
source: "Parkinson's Pathways (curated)"
---
# Map rescue medication dosing patterns

**Goal (in five words):** Map rescue medication dosing patterns

**Official Title:** SL-APO in the Treatment of Patients With Parkinson's Disease: a Real-world Evidence Study to Identify Titration and Usage Schemes - SL-START

**Trial ID:** [NCT07145190](https://clinicaltrials.gov/study/NCT07145190)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Bial - Portela C S.A.
- **Target Enrollment:** 90 participants
- **Start Date:** 2025-08-27
- **Completion Date:** 2028-02
- **Conditions:** Parkinson Disease
- **Interventions:** SL-APO
- **Intervention Types:** DRUG

## Summary For Families

The goal is to map how people actually start and use sublingual apomorphine for OFF episodes, so doctors and patients can learn practical titration and dosing patterns. Participants who are beginning SL-APO per the product label will be followed without changing their care; apomorphine is a fast-acting dopamine agonist that directly stimulates dopamine receptors to quickly reverse OFF symptoms, working as a rescue on top of regular levodopa rather than replacing it. The study seeks adults 18 and older with idiopathic Parkinson's who are about to start SL-APO and are not already on a titration or maintenance dose, and it excludes people with dementia, psychotic disorders, other contraindications on the product label, or who are in another investigational drug trial.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* The patient is ≥ 18 years of age.
* The patient has a clinical diagnosis of idiopathic Parkinson's disease.
* The patient will initiate SL-APO for the treatment of OFF episodes according to the SmPC.
* The patient is not currently on titration or maintenance dose for SL-APO.
* The patient has provided written informed consent to participate in this study.

Exclusion Criteria:

* The patient is participating in a clinical trial with an investigational drug.
* The patient has presented with dementia or evidence of cognitive decline as determined by the investigator.
* The patient has a history of psychotic disorder.
* The patient presents any other contraindication according to the SL-APO SmPC.
```

## Locations (12)

- Charité - Universitätsmedizin Berlin - Sektion für Bewegungsstörungen und Neuromodulation, Berlin, Germany _(52.5244, 13.4105)_
  - Patricia Krause, Dr. med. — (CONTACT) — patricia.krause@charite.de
- Alexianer St. Joseph Berlin-Weißensee GmbH, Berlin, Germany _(52.5244, 13.4105)_
  - Thomas Müller, Prof Dr med — (CONTACT) — 03092790-301/223/703 — Th.Mueller@alexianer.de
- Praxis für Neurologie, Berlin, Germany _(52.5244, 13.4105)_
  - Martin Delf, Dr. med. — (CONTACT) — 03342422930 — dr.delf@neuroprax.de
- Katholisches Klinikum Bochum gGmbH, Universitätsklinikum St.Josef-Hospital, Klinik für Neurologie, Bochum, Germany _(51.4817, 7.2165)_
  - Siegfried Muhlack, Prof. Dr. — (CONTACT) — 0234509-0 — siegfried.muhlack@rub.de
- UNIVERSITÄTSKLINIKUM FREIBURG - Neurozentrum Klinik für Neurologie und Neurophysiologie im Neurozentrum, Freiburg im Breisgau, Germany _(47.9959, 7.8522)_
  - Michel Rijntjes, Prof Dr med — (CONTACT) — 076127053570
- Praxis für Neurologie und Psychiatrie, Fulda, Germany _(50.5516, 9.6752)_
  - Fabian Sprengel, Dr. — (CONTACT) — info@neuro-fulda.de
- Klinik am Tharandter Wald, Hetzdorf, Germany _(53.4341, 13.7111)_
  - Peter Themann, Dr. — (CONTACT) — 03520927711 — themann@reha-hetzdorf.de
- Klinik für Neurologie und Neurologische Frührehabilitation, Osnabrück, Germany _(52.2726, 8.0498)_
  - Tobias Warnecke, Prof. Dr. — (CONTACT) — 05414056501 — tobias.warnecke@klinikum-os.de
- Die Nerven Docs, Siegen, Germany _(50.8748, 8.0243)_
  - Markus Diedrichs — (CONTACT) — 027152455 — m.diedrichs@neurologiesiegen.de
- Neurologische Klinik Sorpesee, Sundern, Germany _(51.3281, 8.0037)_
  - Pan-Montojo Puga, Prof. Dr. — (CONTACT) — 02935807336 — francisco.pan-montojo@klinik-sorpesee.de
- Praxis für Neurologie und Geriatrie, Ulm, Germany _(48.3984, 9.9916)_
  - Jan Kassubek, Prof Dr med — (CONTACT) — 073166400 — jan.kassubek@uni-ulm.de
- Neurologie am Funkerberg, Wusterhausen, Germany _(52.8912, 12.4602)_
  - Andreas Funke, Dr. med. — (CONTACT) — 01709095741

## Central Contacts

- Ruben Arnelas — (CONTACT) — +351229866100 — clinical.trials@bial.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07145190*  
*HTML version: https://parkinsonspathways.com/trial/NCT07145190*  
*Source data: https://clinicaltrials.gov/study/NCT07145190*